Search Result

Results for "

renal impairment

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (2) Apoptosis (1) Autophagy (3) Bcl-2 Family (1) Biochemical Assay Reagents (2) Cannabinoid Receptor (1) Dipeptidyl Peptidase (4) E1/E2/E3 Enzyme (1) HSP (1) Isotope-Labeled Compounds (2) Mitochondrial Metabolism (1) Reactive Oxygen Species (ROS) (1) YAP (1)
By Research Areas:	Cancer (1) Endocrinology (1) Inflammation/Immunology (4) Metabolic Disease (6) Neurological Disease (4)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-117985B

Evogliptin tartrate DA-1229 tartrate	Dipeptidyl Peptidase Autophagy	Metabolic Disease Inflammation/Immunology
Evogliptin (DA-1229) tartrate is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin tartrate also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin tartrate can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .

HY-W019894

Manganese chloride Manganese dichloride	Biochemical Assay Reagents	Others
Manganese chloride is a new oral active magnetic resonance liver contrast agent for patients with renal impairment .

HY-W250122

Glutamic acid sodium salt Monosodium glutamate	Biochemical Assay Reagents Reactive Oxygen Species (ROS) Mitochondrial Metabolism Apoptosis HSP Bcl-2 Family	Neurological Disease Metabolic Disease Inflammation/Immunology
Glutamic acid sodium salt (Monosodium glutamate) is an orally active food flavor enhancer. Glutamic acid sodium salt causes ROS generation, mitochondrial dysfunction, and Apoptosis. Glutamic acid sodium salt upregulates CHOP, Grp78, and Bcl-2. Glutamic acid sodium salt impairs cognition, induces depressive-like behavior, induces hyperalgesia, and induces obesity and insulin resistance. Glutamic acid sodium salt can be used to study neurotoxicity (e.g., brain damage, cognitive impairment), metabolic disorders (e.g., obesity, insulin resistance), hepatotoxicity, and renal toxicity, as well as pain-related disorders .

HY-110206

AM6545	Cannabinoid Receptor	Metabolic Disease
AM6545 is a highly selective, brain-free (peripherally active) CB1 receptor antagonist (K_i=1.7 nM). AM6545 inhibits endocannabinoid signaling by competitively antagonizing CB1 receptors, inhibiting CB1-mediated appetite stimulation and inflammatory responses without affecting cAMP levels. AM6545 significantly reduces food intake and body weight in mice, while improving metabolic syndrome-related renal impairment (such as proteinuria, fibrosis) and insulin resistance. AM6545 can be used in the study of obesity and its complications .

HY-10965

Rolofylline KW-3902	Adenosine Receptor	Neurological Disease
Rolofylline (KW-3902) is a potent, selective adenosine A1 receptor antagonist that is under development for the treatment of patients with acute congestive heart failure and renal impairment. Rolofylline is metabolized primarily to the pharmacologically active M1-trans and M1-cis metabolites by cytochrome P450 (CYP₄₅₀) . Rolofylline is alleviating the presynaptic dysfunction and restores neuronal activity as well as dendritic spine levels in vitro, is an interesting candidate to combat the hypometabolism and neuronal dysfunction associated with Tau-induced neurodegenerative diseases .

HY-117985

Evogliptin DA-1229	Dipeptidyl Peptidase Autophagy	Metabolic Disease Inflammation/Immunology
Evogliptin (DA-1229) is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .

HY-176305S

Neurofilament, U-15N	Isotope-Labeled Compounds	Neurological Disease
Neurofilament, U- ¹⁵N is the ¹⁵N-labeled Neurofilament.

HY-175247

DDO-4033	E1/E2/E3 Enzyme YAP	Cancer
DDO-4033 is a SPOP inhibitor (IC₅₀ = 16.9 μM, K_d = 15.1 μM). DDO-4033 impairs the malignant migration, invasion, and proliferation of clear cell renal cell carcinoma (ccRCC) cell lines. DDO-4033 disrupts SPOP recruitment to its substrate LATS1, inhibits its polyubiquitination and subsequent degradation, and upregulates LATS1 expression. DDO-4033 has promising antitumor activity and is promising for renal cell carcinoma research .

HY-117985A

Evogliptin hydrochloride DA-1229 hydrochloride	Dipeptidyl Peptidase	Metabolic Disease Endocrinology
Evogliptin hydrochloride (DA-1229 hydrochloride) is an orally available DPP4 inhibitor with significant and durable hypoglycemic effects in mouse models. Evogliptin hydrochloride also inhibits the generation of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin hydrochloride can be used in the research of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .

HY-117985S

Evogliptin-d9 DA-1229-d₉	Isotope-Labeled Compounds Autophagy Dipeptidyl Peptidase	Metabolic Disease Inflammation/Immunology
Evogliptin-d₉ (DA-1229-d₉) is deuterium labeled Evogliptin. Evogliptin (DA-1229) is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .

HY-10965R

Rolofylline (Standard)	Adenosine Receptor	Neurological Disease
Rolofylline (Standard) is the analytical standard of Rolofylline. This product is intended for research and analytical applications. Rolofylline (KW-3902) is a potent, selective adenosine A1 receptor antagonist that is under development for the treatment of patients with acute congestive heart failure and renal impairment. Rolofylline is metabolized primarily to the pharmacologically active M1-trans and M1-cis metabolites by cytochrome P450 (CYP450) . Rolofylline is alleviating the presynaptic dysfunction and restores neuronal activity as well as dendritic spine levels in vitro, is an interesting candidate to combat the hypometabolism and neuronal dysfunction associated with Tau-induced neurodegenerative diseases .

Cat. No.	Product Name	Type

HY-W250122

Glutamic acid sodium salt Monosodium glutamate	Biochemical Assay Reagents
Glutamic acid sodium salt (Monosodium glutamate) is an orally active food flavor enhancer. Glutamic acid sodium salt causes ROS generation, mitochondrial dysfunction, and Apoptosis. Glutamic acid sodium salt upregulates CHOP, Grp78, and Bcl-2. Glutamic acid sodium salt impairs cognition, induces depressive-like behavior, induces hyperalgesia, and induces obesity and insulin resistance. Glutamic acid sodium salt can be used to study neurotoxicity (e.g., brain damage, cognitive impairment), metabolic disorders (e.g., obesity, insulin resistance), hepatotoxicity, and renal toxicity, as well as pain-related disorders .

Glutamic acid sodium salt

Monosodium glutamate

Biochemical Assay Reagents

Glutamic acid sodium salt (Monosodium glutamate) is an orally active food flavor enhancer. Glutamic acid sodium salt causes ROS generation, mitochondrial dysfunction, and Apoptosis. Glutamic acid sodium salt upregulates CHOP, Grp78, and Bcl-2. Glutamic acid sodium salt impairs cognition, induces depressive-like behavior, induces hyperalgesia, and induces obesity and insulin resistance. Glutamic acid sodium salt can be used to study neurotoxicity (e.g., brain damage, cognitive impairment), metabolic disorders (e.g., obesity, insulin resistance), hepatotoxicity, and renal toxicity, as well as pain-related disorders .

Cat. No.	Product Name	Chemical Structure

HY-176305S

Neurofilament, U-15N
Neurofilament, U- ¹⁵N is the ¹⁵N-labeled Neurofilament.

HY-117985S

Evogliptin-d9
Evogliptin-d₉ (DA-1229-d₉) is deuterium labeled Evogliptin. Evogliptin (DA-1229) is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .

Evogliptin-d9

Evogliptin-d₉ (DA-1229-d₉) is deuterium labeled Evogliptin. Evogliptin (DA-1229) is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .

Cat. No.	Product Name		Classification

HY-175247

DDO-4033		Alkynes
DDO-4033 is a SPOP inhibitor (IC₅₀ = 16.9 μM, K_d = 15.1 μM). DDO-4033 impairs the malignant migration, invasion, and proliferation of clear cell renal cell carcinoma (ccRCC) cell lines. DDO-4033 disrupts SPOP recruitment to its substrate LATS1, inhibits its polyubiquitination and subsequent degradation, and upregulates LATS1 expression. DDO-4033 has promising antitumor activity and is promising for renal cell carcinoma research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.